OB/Gyn
Menopause
More in Menopause
Analyses of current or former use, duration of use, social factors fail to show an association
As few as one infusion per decade lowered risk
Revisions could yield substantive changes for screening in younger women, say editorialists
The warning highlights known risk of rare but serious liver injury associated with fezolinetant
Selected highlights from the 2024 American College of Gastroenterology annual meeting
Also in TTHealthWatch: menopause hormone therapy in the U.S.
Survey indicates persistent pain and re-intervention may play a role
Cognitive behavioral therapy tied to better satisfaction and desire
E4Comfort II trial also found improvements in quality of life and markers of bone health
No association between earlier violence and processing speed, verbal memory
No adverse liver effects seen with elinzanetant in OASIS 3 trial
Meta-analysis of 23 randomized trials showed lower HOMA-IR
Despite renewed spotlight on menopause, use by insured still hasn't rebounded
Clinicians should perform liver blood tests before and during Veozah treatment
